11:10 AM EST, 12/02/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) developing therapeutic options for sepsis and septic shock, on Monday said medical supply disruptions have impacted patient enrollment for its Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in adults treated for endotoxemia and septic shock.

The company says 136 patients were enrolled at end of November and enrollment was impacted in October and November due to Hurricane Helene's disruption of the medical supply chain.

While the disruption in production of critical intravenous fluids persists, management believes these are short term and is projecting full enrollment closer to the end of the first quarter of next year.

Spectral shares were last seen down $0.01 to $0.55 on the Toronto Stock Exchange.

Price: 0.55, Change: -0.01, Percent Change: -1.79